The patients allocated to 3-year adjuvant imatinib had longer OS than those allocated to 1 year of adjuvant imatinib when GIST harboured KIT exon 11 deletion/indel mutation (HR 0.09, 95% CI, 0.01–0.74; p = 0.016). This evidence concerns the gene KIT and gastrointestinal stromal tumor.